A study conducted in 2014 found that higher concentrations of CBD may be required until the effects take hold. The study was conducted on transgenic mice.
Alzheimer’s is the most common form of dementia, so dementia is just a category that Alzheimer’s Disease belongs to. Yet, there are other forms of dementia besides Alzheimer’s.
In clinical trials, researchers have found that the endocannabinoid system is involved in neurotransmission, neuropathology, and neurobiology of different forms of dementia, including Alzheimer’s Disease.
What Experts Say About CBD Oil and Dementia
“Most often, people associate Alzheimer’s disease with memory problems, but this is just one aspect of a complex condition that can affect people in different ways. Many people with Alzheimer’s can become agitated or aggressive, and this can pose difficulties for the person with the condition and those closest to them.”
Researchers will be investigating the efficacy of Sativex, a drug already approved for patients with multiple sclerosis, by observing 60 patients between the age of 55–90 who are living in care homes for the duration of the trial. The study will aim at easing aggression and agitation, one of the main symptoms of dementia.
Scientists suggest that Parkinson’s disease may derive from lowered dopamine production and is most commonly expressed by muscular strains, tremors, and slow, flawed movement.
“With no new dementia treatments in over 15 years, it is vital that we test a wide range of approaches to find effective ways to help people living with the condition,” said David Reynolds, Ph.D., of Alzheimer’s Research U.K. Reynolds underlines the importance of finding a medicine that will not only slow or stop the progression of dementia but also benefits people’s day-to-day performance.
Currently there is no evidence to show that cannabis or cannabis oil (CBD oil) can stop, reverse or prevent dementia.
There are no research studies that prove cannabis, or products such as cannabis oil (CBD oil), can stop, slow, reverse or prevent the diseases that cause dementia.
What is cannabis?
But more research is needed to understand the long-term effects of taking cannabis, and whether it is an effective and safe way to tackle dementia symptoms.
Research does suggest that high concentrations of CBD oil could be useful for managing some of the symptoms of dementia such as agitation and anxiety.
This is because we have not received any high-quality applications from researchers intending to investigate these issues.
March 25, 2021 07:30 ET | Source: CBD Global Sciences Inc. CBD Global Sciences Inc.
Denver, Colorado, March 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — CBD Global Sciences, Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt:GS3), (“CBD Global” or the “Company”), is pleased to share that a recent study has revealed that CBD may be key to stopping triggers for Alzheimer’s disease, according to researchers from the Medical College of Georgia in Augusta University.
Cannabidiol, or CBD, continues to gain support as a remedy for everything from stress to bacterial infections. A new study reveals marijuana’s non-psychoactive ingredient may also be the key to stopping the triggers for Alzheimer’s disease. Researchers from the Medical College of Georgia at Augusta University say high doses of CBD restores the function of key proteins that clean up beta-amyloid plaque buildups in the brain. These clumps are one of the major causes of Alzheimer’s disease, the most common form of dementia.
CBD Global Sciences, Inc., is a vertically integrated hemp-based CBD producer and branding investment vehicle which currently owns two product categories, branded under the name Aethics™ (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals, Hydration products and Confectionary products. CBD Global Sciences hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.